Charles River Laboratories (CRL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2005 | 12-2004 | 12-2003 | 12-2002 | 12-2001 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 114,821 | 207,566 | 182,331 | 127,509 | 58,271 |
| Marketable Securities | N/A | N/A | 13,156 | N/A | N/A |
| Receivables | 171,259 | 201,794 | 111,514 | 94,245 | 98,478 |
| Inventories | 65,128 | 61,914 | 52,370 | 43,892 | 39,056 |
| Other current assets | 68,114 | 39,032 | 11,517 | 12,446 | 14,349 |
| TOTAL | $419,322 | $510,306 | $370,888 | $278,092 | $210,154 |
| Non-Current Assets | |||||
| PPE Net | 387,501 | 357,149 | 203,458 | 187,875 | 155,919 |
| Investments And Advances | 0 | 0 | 0 | 0 | 3,002 |
| Intangibles | 1,272,611 | 1,678,880 | 135,723 | 130,736 | 90,374 |
| Other Non-Current Assets | 458,775 | 80,500 | 89,485 | 104,641 | 111,913 |
| TOTAL | $2,118,887 | $2,116,529 | $428,666 | $423,252 | $361,208 |
| Total Assets | $2,538,209 | $2,626,835 | $799,554 | $701,344 | $571,362 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 36,263 | 80,865 | 319 | N/A | N/A |
| Accounts payable and accrued liabilities | 28,727 | 28,672 | 19,433 | 13,084 | 13,868 |
| Accrued Expenses | 76,863 | 97,759 | 56,094 | 60,182 | 54,635 |
| Other current liabilities | 43,581 | 24,329 | 7,659 | 6,038 | 3,771 |
| TOTAL | $311,412 | $349,115 | $114,351 | $113,369 | $98,532 |
| Non-Current Liabilities | |||||
| Long Term Debt | 259,902 | 605,980 | 185,683 | 192,484 | 155,506 |
| Deferred Revenues | 95,564 | 117,490 | 30,846 | 27,029 | 22,210 |
| Other Non-Current Liabilities | 139,882 | 199,235 | 34,897 | 26,920 | 16,070 |
| TOTAL | $399,784 | $805,215 | $220,580 | $230,599 | $183,320 |
| Total Liabilities | $711,196 | $1,154,330 | $334,931 | $343,968 | $281,852 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 71,992 | 66,110 | 46,075 | 44,742 | 44,234 |
| Common Shares | 724 | 658 | 458 | 452 | 442 |
| Retained earnings | 78,906 | -63,093 | -152,885 | -233,036 | -283,168 |
| Other shareholders' equity | -12,242 | 16,086 | 7,269 | -11,768 | -16,673 |
| TOTAL | $1,827,013 | $1,472,505 | $464,623 | $357,376 | $289,510 |
| Total Liabilities And Equity | $2,538,209 | $2,626,835 | $799,554 | $701,344 | $571,362 |